Lifesci Capital Issues Optimistic Forecast for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities researchers at Lifesci Capital lifted their FY2025 EPS estimates for Protara Therapeutics in a report released on Monday, November 10th. Lifesci Capital analyst C. Zhu now anticipates that the company will post earnings of ($1.31) per share for the year, up from their prior estimate of ($1.51). The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. Lifesci Capital also issued estimates for Protara Therapeutics’ Q4 2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.73) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.60.

Protara Therapeutics Price Performance

Protara Therapeutics stock opened at $5.30 on Thursday. The stock has a market cap of $204.48 million, a price-to-earnings ratio of -3.27 and a beta of 1.59. The firm has a 50-day moving average of $4.46 and a two-hundred day moving average of $3.62. Protara Therapeutics has a 1 year low of $2.21 and a 1 year high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.08.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Protara Therapeutics in the 2nd quarter worth approximately $30,000. Quadrature Capital Ltd purchased a new position in Protara Therapeutics during the second quarter valued at approximately $35,000. JPMorgan Chase & Co. bought a new position in Protara Therapeutics in the second quarter worth approximately $46,000. Los Angeles Capital Management LLC purchased a new stake in Protara Therapeutics during the second quarter worth $47,000. Finally, Intech Investment Management LLC purchased a new stake in Protara Therapeutics during the second quarter worth $49,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.